Investigation of the ameliorative effects of baicalin against arsenic trioxide-induced cardiac toxicity in mice. 2021

Xiaoqi Sun, and Xiaotian Wang, and Qianqian He, and Muqing Zhang, and Li Chu, and Yang Zhao, and Yongchao Wu, and Jianping Zhang, and Xue Han, and Xi Chu, and Zhonglin Wu, and Shengjiang Guan
School of Pharmacy, Hebei University of Chinese Medicine, Shijiazhuang 050200, Hebei, China.

Baicalin (BA), a kind of flavonoids compound, comes from Scutellaria baicalensis Georgi (a kind of perennial herb) and has beneficial effects on the cardiovascular system through anti-oxidant, anti-inflammation, and anti-apoptosis actions. However, the therapeutic effects and latent mechanisms of BA on arsenic trioxide (ATO)-induced cardiac toxicity has not been reported. The present research was performed to explore the effects and mechanisms of BA on ATO-induced heart toxicity. Male Kunming mice were treated with ATO (7.5 mg/kg) to induce cardiac toxicity. After the mice received ATO, BA (50 and 100 mg/kg) was administered for estimating its cardioprotective effects. Statistical data demonstrated that BA treatment alleviated electrocardiogram abnormalities and pathological injury caused by ATO. BA could also lead to recovery of CK and LDH activities to normal range and cause a decrease in MDA levels and ROS generation, augmentation of SOD, CAT, and GSH activities. We also found that BA caused a reduction in the expression of proinflammatory cytokines, such as TNF-α and IL-6. Moreover, BA attenuated ATO-induced apoptosis by promoting the expression of Bcl-2 and suppressing the expression of Bax and caspase-3. TUNEL test result demonstrated BA caused impediment of ATO-induced apoptosis. Furthermore, BA treatment suppressed the high expression of TLR4, NF-κB and P-NF-κB caused by ATO. In conclusion, these results indicate that BA may alleviate ATO-induced cardiac toxicity by restraining oxidative stress, apoptosis, and inflammation, and its mechanism would be associated with the inhibition of the TLR4/NF-κB signaling pathway.

UI MeSH Term Description Entries
D007249 Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function. Innate Inflammatory Response,Inflammations,Inflammatory Response, Innate,Innate Inflammatory Responses
D008297 Male Males
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D005419 Flavonoids A group of phenyl benzopyrans named for having structures like FLAVONES. 2-Phenyl-Benzopyran,2-Phenyl-Chromene,Bioflavonoid,Bioflavonoids,Flavonoid,2-Phenyl-Benzopyrans,2-Phenyl-Chromenes,2 Phenyl Benzopyran,2 Phenyl Benzopyrans,2 Phenyl Chromene,2 Phenyl Chromenes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077237 Arsenic Trioxide An inorganic compound with the chemical formula As2O3 that is used for the treatment of ACUTE PROMYELOCYTIC LEUKEMIA in patients who have relapsed from, or are resistant to, conventional drug therapy. Arsenic Oxide (As2O3),Arsenic Oxide (As4O6),Arsenic(III) Oxide,Arsenolite,Arsenous Anhydride,As2O3,As4O6,Diarsenic Trioxide,Naonobin,Tetra-Arsenic Hexaoxide,Tetra-Arsenic Oxide,Tetraarsenic Hexaoxide,Tetraarsenic Oxide,Trisenox,Trixenox,Tetra Arsenic Hexaoxide,Tetra Arsenic Oxide
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D015398 Signal Transduction The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway. Cell Signaling,Receptor-Mediated Signal Transduction,Signal Pathways,Receptor Mediated Signal Transduction,Signal Transduction Pathways,Signal Transduction Systems,Pathway, Signal,Pathway, Signal Transduction,Pathways, Signal,Pathways, Signal Transduction,Receptor-Mediated Signal Transductions,Signal Pathway,Signal Transduction Pathway,Signal Transduction System,Signal Transduction, Receptor-Mediated,Signal Transductions,Signal Transductions, Receptor-Mediated,System, Signal Transduction,Systems, Signal Transduction,Transduction, Signal,Transductions, Signal
D016328 NF-kappa B Ubiquitous, inducible, nuclear transcriptional activator that binds to enhancer elements in many different cell types and is activated by pathogenic stimuli. The NF-kappa B complex is a heterodimer composed of two DNA-binding subunits: NF-kappa B1 and relA. Immunoglobulin Enhancer-Binding Protein,NF-kappa B Complex,Nuclear Factor kappa B,Transcription Factor NF-kB,kappa B Enhancer Binding Protein,Ig-EBP-1,NF-kB,NF-kappaB,Nuclear Factor-Kappab,Complex, NF-kappa B,Enhancer-Binding Protein, Immunoglobulin,Factor NF-kB, Transcription,Factor-Kappab, Nuclear,Ig EBP 1,Immunoglobulin Enhancer Binding Protein,NF kB,NF kappa B Complex,NF kappaB,NF-kB, Transcription Factor,Nuclear Factor Kappab,Transcription Factor NF kB

Related Publications

Xiaoqi Sun, and Xiaotian Wang, and Qianqian He, and Muqing Zhang, and Li Chu, and Yang Zhao, and Yongchao Wu, and Jianping Zhang, and Xue Han, and Xi Chu, and Zhonglin Wu, and Shengjiang Guan
September 2001, Blood,
Xiaoqi Sun, and Xiaotian Wang, and Qianqian He, and Muqing Zhang, and Li Chu, and Yang Zhao, and Yongchao Wu, and Jianping Zhang, and Xue Han, and Xi Chu, and Zhonglin Wu, and Shengjiang Guan
September 2001, Blood,
Xiaoqi Sun, and Xiaotian Wang, and Qianqian He, and Muqing Zhang, and Li Chu, and Yang Zhao, and Yongchao Wu, and Jianping Zhang, and Xue Han, and Xi Chu, and Zhonglin Wu, and Shengjiang Guan
October 2021, Biological trace element research,
Xiaoqi Sun, and Xiaotian Wang, and Qianqian He, and Muqing Zhang, and Li Chu, and Yang Zhao, and Yongchao Wu, and Jianping Zhang, and Xue Han, and Xi Chu, and Zhonglin Wu, and Shengjiang Guan
May 2021, Environmental science and pollution research international,
Xiaoqi Sun, and Xiaotian Wang, and Qianqian He, and Muqing Zhang, and Li Chu, and Yang Zhao, and Yongchao Wu, and Jianping Zhang, and Xue Han, and Xi Chu, and Zhonglin Wu, and Shengjiang Guan
January 2022, International journal of immunopathology and pharmacology,
Xiaoqi Sun, and Xiaotian Wang, and Qianqian He, and Muqing Zhang, and Li Chu, and Yang Zhao, and Yongchao Wu, and Jianping Zhang, and Xue Han, and Xi Chu, and Zhonglin Wu, and Shengjiang Guan
December 2020, Molecular medicine reports,
Xiaoqi Sun, and Xiaotian Wang, and Qianqian He, and Muqing Zhang, and Li Chu, and Yang Zhao, and Yongchao Wu, and Jianping Zhang, and Xue Han, and Xi Chu, and Zhonglin Wu, and Shengjiang Guan
January 2011, Journal of pharmacological sciences,
Xiaoqi Sun, and Xiaotian Wang, and Qianqian He, and Muqing Zhang, and Li Chu, and Yang Zhao, and Yongchao Wu, and Jianping Zhang, and Xue Han, and Xi Chu, and Zhonglin Wu, and Shengjiang Guan
January 2011, Journal of pharmacological sciences,
Xiaoqi Sun, and Xiaotian Wang, and Qianqian He, and Muqing Zhang, and Li Chu, and Yang Zhao, and Yongchao Wu, and Jianping Zhang, and Xue Han, and Xi Chu, and Zhonglin Wu, and Shengjiang Guan
April 2023, Research in pharmaceutical sciences,
Xiaoqi Sun, and Xiaotian Wang, and Qianqian He, and Muqing Zhang, and Li Chu, and Yang Zhao, and Yongchao Wu, and Jianping Zhang, and Xue Han, and Xi Chu, and Zhonglin Wu, and Shengjiang Guan
January 2023, Molecular biology reports,
Copied contents to your clipboard!